Guanfacine Tablet, Extended Release
Product Images NDC 70436-042

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Guanfacine (NDC 70436-042). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Slate Run Pharmaceuticals, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1mg-100ct.jpg (1mg 100ct)

Label for Guanfacine Extended-Release Tablets, 1 mg strength, oral dosage form. The label indicates 100 tablets per package and is distributed by Slate Run Pharmaceuticals, LLC. Storage instructions and manufacturer information (Yichang Humanwell Oral Solid Dosage Plant, China) are included. The label also notes tablets should not be crushed, chewed, or broken before swallowing.*

FDA Label Image

2mg-100ct (2mg 100ct)

Label for Guanfacine Extended-Release Tablets 2 mg, oral dosage form, manufactured by Yichang Humanwell Oral Solid Dosage Plant and distributed by Slate Run Pharmaceuticals, LLC. The label indicates a package size of 100 tablets and advises not to crush, chew, or break tablets before swallowing. Storage instructions and barcode are also visible.*

FDA Label Image

3mg-100ct (3mg 100ct)

Label for Guanfacine Extended-Release Tablets, 3 mg strength, oral dosage form. The label includes the NDC number 70436-041-01 and contains warnings about not crushing, chewing, or breaking tablets. It states the product is manufactured by Yichang Humanwell Oral Solid Dosage Plant in China and distributed by Slate Run Pharmaceuticals, LLC, Columbus, Ohio. The package contains 100 tablets.*

FDA Label Image

4mg-100ct (4mg 100ct)

The label for Guanfacine Extended-Release Tablets shows a 4 mg strength in a 100 tablet package by Slate Run Pharmaceuticals. It includes storage instructions, a bar code, manufacturer and distributor details, and warnings against crushing or chewing the tablets before swallowing.*

FDA Label Image

Figure-1 (Figure 1)

A pharmacokinetic plasma concentration-time graph comparing Guanfacine Extended-Release 1 mg QD with Immediate-Release Guanfacine 1 mg QD over 24 hours. The y-axis shows guanfacine plasma concentration in ng/mL, and the x-axis shows time in hours. Extended-release maintains steadier plasma levels; immediate-release shows a rapid peak followed by decline.*

FDA Label Image

Figure-2 (Figure 2)

A pharmacokinetic (PK) chart showing fold changes and 90% confidence intervals for Cmax and AUC due to various CYP3A4/5 inhibitors and inducers, as well as oral methylphenidate and lisdexamfetamine dimesylate. The chart compares relative changes with reference values on the x-axis, ranging from 0 to 5.*

FDA Label Image

Figure-3 (Figure 3)

A forest plot chart showing the fold change and 90% confidence intervals for pharmacokinetic parameters (Cmax and AUC) of oral methylphenidate and lisdexamfetamine dimesylate compared to a reference. The x-axis represents the change relative to the reference, ranging from 0.0 to 2.0.*

FDA Label Image

Figure-4 (Figure 4)

A Kaplan-Meier survival curve comparing time to treatment failure over days between placebo and SPD503 groups. The x-axis represents time to treatment failure (days) and the y-axis shows the treatment failure percentage. The solid line indicates placebo, and the dashed line represents SPD503, showing differences in treatment failure rates over time.*

FDA Label Image

Structure (Structure)

Chemical structure of guanfacine hydrochloride showing a dichlorophenyl group attached to an acetamide moiety linked to a guanidine group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.